The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
Beta-Thalassemia
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
-
UCSF Benioff Children's Hospitals, Oakland, California, United States, 94609
University of Minnesota, Minneapolis, Minnesota, United States, 55455
Cohen Children's Medical Center, New Hyde Park, New York, United States, 11040
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104
Texas Children's Hospital, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
bluebird bio,
Himal Lal Thakar, MD, STUDY_DIRECTOR, bluebird bio, Inc.
2043-12